A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of FHND1002 Granules After Single and Multiple Doses in Healthy Adult Volunteers
Latest Information Update: 30 Jan 2025
Price :
$35 *
At a glance
- Drugs FHND 1002 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms FHND1002-I
- Sponsors Jiangsu Chia Tai Fenghai Pharmaceutical
- 30 Jan 2025 New trial record